LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Cancer Program

• LAVA Therapeutics N.V. (NASDAQ: LVTX) hosted a clinical update call focused on initial Phase 1/2a data for LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the American Society of Clinical Oncology and European Hematology Association meetings.

• "Although preliminary, these data support our view of LAVA-051 as a promising candidate that has the potential to overcome challenges of existing T-cell approaches, which frequently show cytokine release syndrome very close to their efficacious dose," said Arnon Kater, LAVA-051 clinical trial investigator.

• Related: LAVA Therapeutics Shares Interim LAVA-051 Data From Early-Stage Cancer Trial.

• The early clinical data from the first four cohorts demonstrate early signals of potential anti-tumor activity in CLL and MM patients and an attractive safety profile, Kater added.

• Notably, the pharmacodynamic determinations gathered from the patients in the early clinical study reflect the mechanism of action of LAVA-051, he added.

• LAVA-051 is a humanized Gammabody designed to activate both Vγ9Vδ2 (Vgamma9 Vdelta2) T cells and type 1 NKT cells to kill CD1d-expressing tumor cells.

• Price Action: LVTX shares closed at $2.78 on Thursday.

See more from Benzinga

• Rhythm Pharma Secures Non-Dilutive Financing Of $100M To Use Of This...

• HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.